X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (193) 193
humans (185) 185
female (114) 114
male (107) 107
adult (97) 97
middle aged (91) 91
thyroid neoplasms - pathology (86) 86
endocrinology & metabolism (79) 79
cancer (70) 70
carcinoma (68) 68
aged (66) 66
thyroid neoplasms - genetics (61) 61
oncology (60) 60
abridged index medicus (52) 52
immunohistochemistry (44) 44
tumors (42) 42
mutation (39) 39
expression (38) 38
aged, 80 and over (37) 37
thyroid cancer (37) 37
prognosis (36) 36
thyroid neoplasms - metabolism (35) 35
animals (33) 33
surgery (31) 31
carcinoma, papillary - pathology (28) 28
proto-oncogene proteins b-raf - genetics (28) 28
adolescent (27) 27
carcinoma - pathology (25) 25
diagnosis (25) 25
metastasis (25) 25
carcinoma, papillary - genetics (24) 24
mice (24) 24
pathology (23) 23
gene expression regulation, neoplastic (22) 22
research (22) 22
thyroid (22) 22
thyroid cancer, papillary (21) 21
young adult (20) 20
gene expression (19) 19
retrospective studies (19) 19
genetic aspects (18) 18
neoplasm invasiveness (18) 18
nodules (18) 18
analysis (17) 17
child (17) 17
breast-cancer (15) 15
carcinoma, papillary (15) 15
cell line (15) 15
cell line, tumor (15) 15
growth (15) 15
phenotype (15) 15
proto-oncogene proteins - genetics (15) 15
reverse transcriptase polymerase chain reaction (15) 15
thyroid neoplasms - diagnosis (15) 15
tumor cells, cultured (15) 15
carcinoma - genetics (14) 14
carcinoma, papillary - metabolism (14) 14
care and treatment (14) 14
cell biology (14) 14
cells, cultured (14) 14
gene mutations (14) 14
thyroid neoplasms - surgery (14) 14
apoptosis (13) 13
braf (13) 13
cytology (13) 13
dna mutational analysis (13) 13
fine-needle-aspiration (13) 13
transfection (13) 13
follow-up studies (12) 12
gene (12) 12
management (12) 12
mutations (12) 12
point mutation (12) 12
polymerase chain reaction (12) 12
prevalence (12) 12
proto-oncogene proteins c-ret - genetics (12) 12
risk factors (12) 12
association (11) 11
benign (11) 11
biopsy, needle (11) 11
development and progression (11) 11
gene-expression (11) 11
lung neoplasms - pathology (11) 11
protein (11) 11
survival (11) 11
thyroid carcinoma (11) 11
thyroid diseases (11) 11
thyroid gland - pathology (11) 11
thyroid neoplasms - epidemiology (11) 11
thyroid nodule - pathology (11) 11
biochemistry & molecular biology (10) 10
biomarkers, tumor - genetics (10) 10
disease progression (10) 10
experience (10) 10
health aspects (10) 10
neoplasm staging (10) 10
progression (10) 10
proteins (10) 10
reproducibility of results (10) 10
survival analysis (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Pathology, ISSN 0046-8177, 08/2016, Volume 54, pp. 134 - 142
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 10/2008, Volume 93, Issue 10, pp. 3943 - 3949
Background: The BRAFV600E mutation is the most frequent genetic alteration in papillary thyroid carcinoma (PTC). The role of BRAFV600E mutation as a poor... 
Journal Article
Journal of Medical Genetics, ISSN 0022-2593, 11/2016, Volume 53, Issue 11, pp. 729 - 734
Background The RET proto-oncogene is responsible for the pathogenesis of hereditary (98%) and sporadic (40%) medullary thyroid carcinoma (MTC). In sporadic... 
ONCOGENE | RAS | GENETICS & HEREDITY | LOW-PREVALENCE | FOLLOW-UP | ENDOCRINE NEOPLASIA TYPE-2 | CARCINOMA | PROTOONCOGENE | SOMATIC MUTATIONS | STRATIFICATION | CLINICOPATHOLOGICAL FEATURES | Thyroid cancer | Prognosis | Research | Risk factors | Oncogenes
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 12/2017, Volume 411, pp. 35 - 43
The identification of new therapeutic strategies is urgently needed for the management of patients affected by anaplastic thyroid cancer (ATC) due to their... 
Tumor xenografts | Irinotecan | Sunitinib | Anaplastic thyroid cancer | Synergism | CARCINOMA XENOGRAFTS | NUDE-MICE | PROAPOPTOTIC ACTIVITY | KINASE INHIBITOR | CELL-LINES | CHEMOTHERAPY | IN-VITRO | FINE-NEEDLE-ASPIRATION | ONCOLOGY | METRONOMIC IRINOTECAN | TUMOR-ASSOCIATED MACROPHAGES | Thyroid Carcinoma, Anaplastic - drug therapy | Apoptosis - drug effects | Humans | Male | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Synergism | Antineoplastic Agents, Phytogenic - administration & dosage | Pyrroles - pharmacology | Animals | Mice, Nude | Pyrroles - administration & dosage | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Indoles - pharmacology | Aged | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Camptothecin - pharmacology | Camptothecin - analogs & derivatives | Antimitotic agents | Models | Thyroid cancer | Endothelial growth factors | Antineoplastic agents | Gene expression | Drugs | Cytotoxicity | Kinases | Cancer therapies | Experiments | Anticancer properties | Cell cycle | Xenografts | Colony-stimulating factor | Vascular endothelial growth factor | Thyroid | Radiation therapy | Patients | Chemotherapy | Medical prognosis | Cell lines | Antitumor activity | Transporter | Cancer | Apoptosis | Tumors | Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 12/2012, Volume 97, Issue 12, pp. 4390 - 4398
Background: The BRAFV600E mutation, the most frequent genetic alteration in papillary thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor.... 
Journal Article
ENDOCRINE-RELATED CANCER, ISSN 1351-0088, 04/2019, Volume 26, Issue 4, pp. 451 - 462
Molecular differentiation between benign (follicular thyroid adenoma (FTA)) and malignant (follicular thyroid carcinoma (FTC)) thyroid neoplasms is... 
bivalent chromatin domains | HYPERMETHYLATION | polycomb genes | EMBRYONIC STEM | PREVALENCE | follicular thyroid neoplasms | NODULES | ONCOLOGY | PATHWAY | ENDOCRINOLOGY & METABOLISM | DNA methylation | GENE-EXPRESSION | CELL SIGNATURE | CANCER-DIAGNOSIS | integrative analysis | MUTATIONS
Journal Article